\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes SecurityIn the amended Horizon Europe work programme, there are no major changes regarding the 2024 Cluster 3 calls that are expected to open in June 2024.
There are a few minor textual changes as well as slight amendments to the budget, including small contributions from the 2025 budget, for "Other actions not subject to calls for proposals" and for small contributions to a number of Mission calls.
The management of calls under the destination Cybersecurity will be entrusted to the European Cybersecurity Industrial, Technology and Research Competence Centre (ECCC) with the implementation of the Increased Cybersecurity 2023 call (HORIZON-CL3-2023-CS-01) and the Increased Cybersecurity 2024 call (HORIZON-CL3-2024-CS-01). This entrustment may take place as soon as the ECCC has reached its financial and operational autonomy expected in the third quarter of 2024.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
